Correctsequence's experimental gene-editing therapy CS-101 has been used to treat a person with SCD for the first time.

The FDA has granted regenerative medicine advanced therapy designation to BEAM-101, a one-time, gene-edited cell therapy for severe SCD.

Parents' childhood trauma may shape emergency care use patterns in their children with sickle cell disease, a study finds.